LabCorp broadens SARS-CoV-2 serology test availability

By LabPulse.com staff writers

April 22, 2020 -- LabCorp is expanding access to its serological tests for SARS-CoV-2 to more hospitals and healthcare organizations.

The serological tests for SARS-CoV-2 are designed for people who may have had COVID-19 symptoms, but are no longer symptomatic. The tests determine the presence of antibodies to the virus and can help to identify individuals who have been exposed. Understanding if an individual has developed antibodies and a potential immune response can be useful in assessing the ability for hospital staff to care for patients.

The company's COVID-19 serological tests will complement existing molecular tests for COVID-19 that currently are available nationwide to healthcare providers and workers and emergency responders. LabCorp's Pixel at-home self-collection test kit for nasal samples was just cleared for use by the U.S. Food and Drug Administration and is being rolled out to health professionals first, followed by consumers.

LabCorp also plans to work with hospitals where it provides laboratory management and technical support services to establish serological testing in their on-site laboratories. As of next week, physicians can direct asymptomatic patients to LabCorp's approximately 2,000 patient service centers for specimen collection for SARS-CoV-2 immunoglobulin G (IgG) testing. In addition, collection for all three SARS-CoV-2 antibody tests will be available to be performed by LabCorp's nearly 6,000 phlebotomists located in physician offices and healthcare facilities nationwide.

LabCorp wins FDA clearance for at-home COVID-19 test
LabCorp has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for its Pixel by LabCorp COVID-19 at-home test kit....
LabCorp, Ciox Health to create COVID-19 patient database
LabCorp and health information management company Ciox Health have announced a partnership to create a patient data registry to help researchers address...
FDA issues EUA for LabCorp coronavirus test
The U.S. Food and Drug Administration (FDA) on March 16 issued an emergency use authorization (EUA) to LabCorp for the company's coronavirus testing kit.
LabCorp launches novel coronavirus test
LabCorp has released a nucleic acid amplification test for detecting the presence of SARS-CoV-2, the virus that causes COVID-19.
LabCorp posts strong financial results for Q4
Life sciences company LabCorp posted strong financial gains for its fourth quarter but mixed results for the entire 2019 fiscal year.

Copyright © 2020 LabPulse.com

Last Updated ls 4/22/2020 12:01:35 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current